Overview
- Cazorla, M. et al. (2011) J. Clin. Invest. 121, 1846.
- Alomone Labs ANA-12 inhibits BDNF-induced ERK1/2 (p42/44 MAPK) phosphorylation in TrkB-expressing HEK 293 cells.Serum-deprived cells were stimulated with 1 ng/ml Recombinant human BDNF protein (#B-250) in the presence of 0 µM, 100 µM and 200 µM ANA-12 (#A-215). Cell proteins were resolved by SDS-PAGE and probed with anti-phospho-ERK1/2.
- Cazorla, M. et al. (2011) J. Clin. Invest. 121, 1846.
- Shirayama, Y. et al. (2015) Eur. Neuropsychopharmacol. 25, 2449.
ANA-12 is a low molecular weight ligand that acts as a selective tropomyosin receptor kinase B (TrkB) antagonist. The compound shows direct binding to TrkB receptor and prevents its activation by BDNF with high potency, without altering TrkA and TrkC functions. The compound is considered to be a valuable tool for studying the BDNF-TrkB signaling pathway1,2.
A study indicated that administration of ANA-12 has successfully reduced anxiety and depression related behaviors tested in mice1.
TrkB receptor and BDNF are key mediators in the pathophysiology of several mood disorders, including drug addiction, anxiety and depression. They play an important role in the regulation of synaptic transmission and plasticity1.
ANA-12 (#A-215) is a highly pure, synthetic, and biologically active compound.